Navigation Links
Jeeven BioSciences, Inc. Announces the Release of its Neuro-X(TM) Serum Free and Xeno Free Tissue Culture Media
Date:10/24/2013

ATLANTA, Oct. 24, 2013 /PRNewswire-iReach/ -- Jeevan BioSciences, Inc. (http://www.jeevanbiosciences.com) a start-up biotechnology company co-founded by Dr. Rodney Nash, PhD, a former Neuroscience Post-Doctoral Fellow at Emory University, today announces the commercial release of its first product Neuro–X Tissue Culture Media; the first 100% Serum Free and Xeno Free media product available on the market. Neuro-X is a proprietary patent pending chemically defined media specifically formulated for use in the growth of human cells and tissue without the need for serum or other animal products. The product was originally developed to support the growth of neuronal cells, but has been engineered to support the growth of multiple types of human cells including U87, HeLa, Neural progenitors, MCF7, Raji, A549, 143B, HS587T, PSCs, Cancer Stem Cells, Foreskin Fibroblasts, as well as MEF and 3T3 mouse cells. Researchers using Neuro-X are discovering that the product supports additional cell types on an almost weekly basis.

"It is well known that serum is essentially a contaminant that significantly affects the ability to obtain reliable and reproducible results when it comes to cell culturing, and we knew that developing a serum free and xeno free media would solve this problem," says Dr. Rodney Nash, CEO of Jeevan BioScience.

Neuro-X is a proprietary DMEM/F-12 base media that contains no animal-derived components or albumin, and efficiently grows all types of human cells and tissue including cancer cells, stem cells, neuronal cells, foreskin fibroblast, and muscle cells. The media also effectively grows mouse cells and other tissue as well. "We are excited about the possibilities when you consider the number of different cell types that Neuro-X supports," continues Dr. Nash; "we constantly hear about additional cell types that the media supports from other researchers around the country that are using the media, and we encourage them to run new experiments and expand the possibilities of their research".

"This media maintains stemness in neuronal progenitor cells" says Dr. Jie Xu, Ph.D. a researcher at Georgia State University.; "we have been able to successfully infect these cells with Sindbis virus and maintain neuronal progenitor cells using Neuro-X media, and now we intend to include this media as an important tool in our research initiatives." Neuro-X media is also being used by cancer researchers across the country. "We are very impressed with Neuro-X in maintaining and differentiating patient glioma tumor-derived (primary cells) cancer stem cell," says Carol Tucker-Burden a researcher at Emory University, "the Neuro-X media maintains the tumor derived neurospheres similarly in comparison to our supplemented media without the need for us to be concerned with serum, which we consider to be a contaminant."

Neuro-X is available at an introductory price of US$199.00 per 500ML bottle, and is distributed by World Wide Medical Products, Inc. (http://www.wwmponline.com), a laboratory products and services company located in Bristol Pennsylvania. "We are very impressed with the Neuro-X product and the team at Jeevan Biosciences," says David Spaventa, Director of Sales & Strategic Alliances at World Wide Medical Products; "prior to our relationship with Jeevan we had never distributed a media product, but decided to distribute Neuro-X given its unique quality as the only true serum free and xeno free media available on the market, and the significant growth potential for a product like this". Free samples of Neuro-X media are available in units of 50mL and 100mL from World Wide Medical Products (1-866-889-9967)

Additional information about the Neuro-X product can be found on the Jeevan Biosciences website (http://www.jeevanbiosciences.com,) including product brochures and scientific papers that provide technical details about how the media is being used in scientific research and drug development.

About Jeevan Bio Sciences, Inc. 
Jeevan Biosciences, Inc. is an Atlanta based biotechnology company committed to the development of cellular models for cancer and neurologic disease research and drug testing. Through accurate cellular model systems, we strive to bridge the gap between research and medicine to improve the quality of life for patient populations who would benefit the most.

Media Contact: Dr. Rodney Nash, Jeevan Biosciences,Inc., (404) 921-2505, info@jeevanbiosciences.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Jeevan BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
2. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
3. Founded by Enlight Biosciences, KNODE partners with AstraZeneca and Other Partners
4. Regado Biosciences, Inc. to Present at the 2012 Wedbush PacGrow Life Sciences Conference in New York, NY
5. Regado Biosciences, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference in Boston, MA
6. Pressure BioSciences, Inc. to Discuss Second Quarter 2012 Financial Results and Provide Business Update
7. Pressure BioSciences, Inc. Reports 70% Revenue Growth for Second Consecutive Quarter
8. Regado Biosciences, Inc. to Present at the UBS Global Life Sciences Conference 2012 in New York, NY
9. Pressure BioSciences, Inc. to Discuss Third Quarter 2012 Financial Results and Provide Business Update
10. Regado Biosciences, Inc. to Present at the Oppenheimer 23rd Annual Healthcare Conference in New York, NY
11. Pressure BioSciences, Inc. to Present at the SeeThruEquity Spring Investor Microcap Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... 2016   , ... Recurring Consumable Sales  Clinical sales grow 16% ... (Euronext: MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary ... the first quarter ended March 31, 2016 and provided ... its commercial strategy. First Quarter 2016 Revenue ...
(Date:4/27/2016)... 27, 2016 Tie-up with Government ... to save newborns   Fortis La ... newborns in collaboration with Breast Milk Foundation (BMF), a non-profit ... Human Milk Bank, ,Amaara, in Delhi-NCR today. This non-profit centre ... for infants and should be available to babies deprived of ...
(Date:4/27/2016)... NEW YORK , April 27, 2016 /PRNewswire/ ... OASM ), a developer of a new ... today announced positive overall survival results for Paclical/Apealea ... total of 789 patients with epithelial ovarian cancer. ... treatment groups: Paclical/Apealea in combination with carboplatin versus ...
Breaking Medicine Technology:
(Date:4/30/2016)... ... April 30, 2016 , ... Saturday, April 30, marks World ... on public health. The World Veterinary Association (WVA) and the World Organization for ... continuing education with a One Health focus, which emphasizes how veterinarians pursue continuing ...
(Date:4/30/2016)... ... ... for all of us, but there are things we can do to improve the odds of ... more and more that there are simple, yet important steps that can be taken to maintain ... Kohli’s recommends for her patients include;, , exercise , ...
(Date:4/29/2016)... (PRWEB) , ... April 30, 2016 , ... Mercy College ... campus. The following programs will be expanding due to high demand: Master of ... The expansion will begin this summer. , School of Business Graduate Program ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... Accreditation Council for Graduate Medical Education (ACGME) that it has received accreditation for ... first accreditation of three residency programs that Memorial is currently pursuing, including Pediatrics ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... On Tuesday, ... hospitals across the Southeast, celebrated the signature of Gov. Nathan Deal on SB 258, ... Geoff Duncan (R - Cumming), offers a 70% tax credit to individuals and corporations ...
Breaking Medicine News(10 mins):